ProCE Banner Activity

TRANSCEND CLL 004: Phase I Results With Lisocabtagene Maraleucel + Ibrutinib in Relapsed/Refractory CLL/SLL

Slideset Download
Conference Coverage
Lisocabtagene maraleucel plus ibrutinib well tolerated with encouraging efficacy in heavily pretreated patients with CLL/SLL.

Released: December 09, 2020

Expiration: December 08, 2021

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Amgen, Inc.

AstraZeneca

Bristol Myers Squibb

Epizyme, Inc.

GlaxoSmithKline

Incyte Corporation

Janssen Biotech

Karyopharm Therapeutics Inc.

Novartis

PharmaEssentia Corp

Seagen

Takeda Oncology